Ticker Details
NovoCure Limited Ordinary Shares NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors.
IPO Date:	September 28, 2015
Sector:	Healthcare
Industry:	Medical Instruments and Supplies
Market Cap:	$2.08B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.25 | 2.70%
Avg Daily Range (30 D):	$0.42 | 2.99%
Avg Daily Range (90 D):	$0.38 | 2.93%

Institutional Daily Volume
Avg Daily Volume:	.82M
Avg Daily Volume (30 D):	1.39M
Avg Daily Volume (90 D):	1.52M

Trade Size
Avg Trade Size (Sh.):	72
Avg Trade Size (Sh.) (30 D):	63
Avg Trade Size (Sh.) (90 D):	64

Institutional Trades
Total Institutional Trades:	5,275
Avg Institutional Trade:	$3.56M
Avg Institutional Trade (30 D):	$2.21M
Avg Institutional Trade (90 D):	$2.33M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.28M
Avg Closing Trade (30 D):	$3.19M
Avg Closing Trade (90 D):	$2.95M
Avg Closing Volume:	115.24K

News

Feb 17, 2026 @ 4:17 PM New Treatment Modalities Are Reaching Cancers That... Source: Prnewswire

Feb 13, 2026 @ 12:34 PM Soleus Adds a Significant Number of Celcuity Share... Source: Lawrence Rothman, Cfa

Feb 12, 2026 @ 5:57 PM FDA Approves First-of-Its-Kind Device to Treat Pan... Source: U.S. Food And Drug Administration

Feb 12, 2026 @ 1:31 PM Stock Market Today: Dow Jones, S&P 500 Futures Gai... Source: Rounak Jain

Sep 29, 2025 @ 8:30 PM Novocure to Present Final Results from the Pivotal... Source: Business Wire

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.22	$-.22	$-1.22
Diluted EPS	$-1.22	$-.22	$-1.22
Revenue	$655.35M	$174.35M	$655.35M
Gross Profit	$488.47M	$132.19M	$488.47M
Net Income / Loss	$-136.23M	$-24.5M	$-136.23M
Operating Income / Loss	$-153.8M	$-40.39M	$-153.8M
Cost of Revenue	$166.88M	$42.16M	$166.88M
Net Cash Flow	$-62.7M	$-241.25M	$-62.7M
PE Ratio